Global PEGylated Proteins Market to Reach $1.8 Billion by 2030
The global market for PEGylated Proteins estimated at US$889.7 Million in the year 2022, is projected to reach a revised size of US$1.8 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2022-2030. Consumables, one of the segments analyzed in the report, is projected to record 8.6% CAGR and reach US$1.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Services segment is readjusted to a revised 10.5% CAGR for the next 8-year period.The U.S. Market is Estimated at $264.5 Million, While China is Forecast to Grow at 8.5% CAGR
The PEGylated Proteins market in the U.S. is estimated at US$264.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$306.3 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.Select Competitors (Total 46 Featured) -
- BIA Separations d.o.o.
- Biomatrik Inc.
- Celares GmbH
- Creative PEGWorks
- IRIS Biotech GmbH
- Jenkem Technology Co., Ltd.
- Thermo Fisher Scientific, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- PEGylated Proteins - Global Key Competitors Percentage Market Share in 2020 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World 8-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
- Table 3: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 4: World 8-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 6: World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World 8-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 9: World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 10: World 8-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 12: World 8-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World 8-Year Perspective for mAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 15: World Recent Past, Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 16: World 8-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 18: World 8-Year Perspective for Other Protein Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 20: World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 21: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 22: World 8-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
- Table 23: World PEGylated Proteins Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- Table 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 25: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 26: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: USA 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 28: USA Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 29: USA 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 30: USA Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 31: USA 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- CANADA
- Table 32: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Canada 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 34: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 35: Canada 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 36: Canada Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 37: Canada 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- JAPAN
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: Japan 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 40: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 41: Japan 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 42: Japan Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 43: Japan 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- CHINA
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 44: China Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: China 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 46: China Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 47: China 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 48: China Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 49: China 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- EUROPE
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 51: Europe 8-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
- Table 52: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 53: Europe 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 54: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 55: Europe 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: Europe 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- FRANCE
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 58: France Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 59: France 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 60: France Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 61: France 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 62: France Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: France 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- GERMANY
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 64: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 65: Germany 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 66: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 67: Germany 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 68: Germany Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: Germany 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- ITALY
- Table 70: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 71: Italy 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 72: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 73: Italy 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 74: Italy Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: Italy 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- UNITED KINGDOM
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 76: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 77: UK 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 78: UK Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 79: UK 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 80: UK Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 81: UK 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- REST OF EUROPE
- Table 82: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 83: Rest of Europe 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 84: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 85: Rest of Europe 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Europe 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- ASIA-PACIFIC
- PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 88: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 89: Asia-Pacific 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 90: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 91: Asia-Pacific 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 93: Asia-Pacific 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
- REST OF WORLD
- Table 94: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 95: Rest of World 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030
- Table 96: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 97: Rest of World 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030
- Table 98: Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of World 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BIA Separations d.o.o.
- Biomatrik Inc.
- Celares GmbH
- Creative PEGWorks
- IRIS Biotech GmbH
- Jenkem Technology Co., Ltd.
- Thermo Fisher Scientific, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 196 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 889.7 Million |
Forecasted Market Value ( USD | $ 1800 Million |
Compound Annual Growth Rate | 9.2% |
Regions Covered | Global |